Resilience MA plant slowdown after Sanofi contract ends
Resilience has reduced operations at a former Sanofi plant in Massachusetts, following the ending of its contract to manufacture enzyme replacement...
Resilience has reduced operations at a former Sanofi plant in Massachusetts, following the ending of its contract to manufacture enzyme replacement therapy, Cerezyme. Contract development manufacturing organization (CDMO) National Resilience has said it is reducing operations at its 310,000 square-foot plant in Allston, Massachusetts, which it acquired from Sanofi in February 2021 . Sanofi itself added the facility through the $20.1 billion acquisition of Genzyme in 2011 . DepositPhotos/ Feverpitch The decision to reduce operations at the facility comes after the contract to manufacture enzyme therapy, Cerezyme (imiglucerase), ended.